InvestorsHub Logo
Followers 2
Posts 436
Boards Moderated 0
Alias Born 01/14/2014

Re: None

Monday, 02/13/2017 5:01:50 PM

Monday, February 13, 2017 5:01:50 PM

Post# of 807
Such high ambitions draw an obvious comparison between Oxford’s humble $158m valuation and the $3.2bn market cap of its lentivirus rival bluebird Bio (NASDAQ:BLUE). Mr Dawson puts this down largely to the fund-raising power of a US biotech; in terms of lentivirus science there is nothing bluebird has done that Oxford has been unable to do, he insists.
HTTP://seekingalpha.com/article/4045447-oxford-biomedica-set-flirt-venture-financing?auth_param=1d8lsm:1ca42qb:f1cd40677110479dbf339020e89a73f0&uprof=82&dr=1